Release issued 15th July 2008

Owing to safety, Escitalopram will remain as the clinical gold standard treatment, according to a new report from Decision Resources

July 15, 2008-Waltham, Mass.-Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug's long-term efficacy in preventing recurrence of depressive mood episodes in patients who suffer from Major Depressive Disorder, is the attribute that most influences psychiatrists' prescribing decisions in the treatment of this disorder. Clinical data and expert opinion show that current and emerging therapies will continue to struggle for patient share through subtle differences in efficacy, tolerability and delivery.

The new report entitled Major Depressive Disorder: Long-Term Efficacy Would Differentiate a New Drug in the Crowded Antidepressant Market finds that if an agent preventing recurrence of depressive mood episodes superior to that of sales-leading Wyeth's Effexor XR were to be launched, it would earn a 25 percent patient share, according to surveyed psychiatrists. The report also finds that although Effexor XR is the sales leader in the major depressive disorder drug market, the current and future Decision Resources proprietary clinical gold standard treatment for the indication is Escitalopram (Lundbeck's Cipralex/Seroplex; Forest's Lexapro).

Although Escitalopram's efficacy is not the highest in our study, the drug outscored any other current therapy in the area of safety. Experts we interviewed explain that because the drug is an active metabolite, lower doses can be used, an advantage that results in safety benefits.

"Based on available data and expert opinion, we do not expect any therapy under development to displace Escitalopram as the clinical gold standard for major depressive disorder," said Carlos Dedesma, Ph.D, analyst at Decision Resources. "Although some therapies in development hold promise, most of them earned inferior scores in efficacy, safety and tolerability, and/or delivery features when compared with Escitalopram."

About the Report
Major Depressive Disorder: Long-Term Efficacy Would Differentiate a New Drug in the Crowded Antidepressant Market is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

(9th September 2008) Glaxo SmithKline’s Lamictal will continue to dominate the epilepsy drug market over the next 10 years

(9th September 2008) Robust sales of Integrilin, Reopro and Aggrastat will drive the

(9th September 2008) Novel oral anticoagulants, particularly Bayer/Ortho-Mcneil’s Xarelto,

(8th September 2008) China’s Hepatitis C virus drug market will grow to $150 million by 2012

(4th September 2008) Physicians eager to increase their first- and second-line prescriptions for Januvia over the next two years for the treatment of type 2 Diabetes